Braeburn

Braeburn Whisky, Trusted Whisky Cask Investment Experts, Launch in United States

Retrieved on: 
Monday, June 12, 2023
Professional Services, Retail, Luxury, Finance, Asset Management, Food, Beverage, Heart, Whisky, Marketing, Regulation D, Multimedia, Research, Broker-dealer, Risk, Sale, Index, Braeburn, Gold, SIPC, Investment, 57th Street (Manhattan), United Kingdom, Scotch whisky, Appendix, Beer, Financial adviser, Financial services, Security (finance), FINRA

Braeburn Whisky, trusted whisky cask investment experts, are pleased to announce the launch of operations in the United States.

Key Points: 
  • Braeburn Whisky, trusted whisky cask investment experts, are pleased to announce the launch of operations in the United States.
  • (Photo: Business Wire)
    With the value of premium whisky consistently appreciating, cask investment has grown in popularity across the globe.
  • Samuel Gordon, President of Braeburn USA said: “Braeburn Whisky is pleased to launch Stateside and offer U.S. investors a secure opportunity to invest in whisky casks.
  • Founded in 2016, Braeburn Whisky offers clients in the United Kingdom, Europe and Asia the opportunity to diversify their portfolios by investing in whisky casks.

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

Retrieved on: 
Wednesday, May 24, 2023
US Foods, Prevalence, Buprenorphine, SC, Senior counsel, Opioid use disorder, OUD, SL, Braeburn, CAMX, Patient, FDA, Food, Pharmaceutical industry, Camurus

Brixadi should be used as part of a complete treatment plan that includes counseling and psychosocial support.1 The product will be marketed in the US by Camurus' licensee Braeburn.

Key Points: 
  • Brixadi should be used as part of a complete treatment plan that includes counseling and psychosocial support.1 The product will be marketed in the US by Camurus' licensee Braeburn.
  • OUD is a complex and potentially life-threatening condition with a significant negative impact on the individual, their families, and society.
  • "Based on the success of Buvidal in Europe, Australia and other territories, we see a significant opportunity for Brixadi in the US," he continues.
  • The product is administered subcutaneously by a healthcare professional as a small volume injection (0.16-0.64 mL) in the buttock, thigh, stomach, or upper arm.

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

Retrieved on: 
Wednesday, May 24, 2023
US Foods, Prevalence, Buprenorphine, SC, Senior counsel, Opioid use disorder, OUD, SL, Braeburn, CAMX, Patient, FDA, Food, Pharmaceutical industry, Camurus

Brixadi should be used as part of a complete treatment plan that includes counseling and psychosocial support.1 The product will be marketed in the US by Camurus' licensee Braeburn.

Key Points: 
  • Brixadi should be used as part of a complete treatment plan that includes counseling and psychosocial support.1 The product will be marketed in the US by Camurus' licensee Braeburn.
  • OUD is a complex and potentially life-threatening condition with a significant negative impact on the individual, their families, and society.
  • "Based on the success of Buvidal in Europe, Australia and other territories, we see a significant opportunity for Brixadi in the US," he continues.
  • The product is administered subcutaneously by a healthcare professional as a small volume injection (0.16-0.64 mL) in the buttock, thigh, stomach, or upper arm.

TROY Group Inc., Launches 4001 and 4101 Printers to Help Combat Check Fraud

Retrieved on: 
Wednesday, February 15, 2023
Product management, Organization, Braeburn, HP, MICR, Fraud, Telephone, OEM, Printing, Security printing, TROY

WHEELING, W.Va., Feb. 15, 2023 /PRNewswire-PRWeb/ -- The TROY 4001 and 4101 MICR Printers are designed for small to medium sized businesses who want a printer with a small footprint and plan to print up to 4,000 checks per month. These low volume printing solutions provide the ability to print MICR fonts and the included TROY E-13B font is specifically designed by TROY to meet worldwide banking standards when used in combination with the TROY 4001/4101 MICR printers and TROY MICR Toner Secure ™.

Key Points: 
  • These low volume printing solutions provide the ability to print MICR fonts and the included TROY E-13B font is specifically designed by TROY to meet worldwide banking standards when used in combination with the TROY 4001/4101 MICR printers and TROY MICR Toner Secure ™.
  • The 4001 and 4101 offer ideal solutions for managing the check printing needs of small businesses or home offices.
  • The 4001 and 4101 which replace the M404 and M428 respectively in the TROY lineup, offer business class features in low volume, efficient, compact desktop printers."
  • To learn more about the TROY 4001 and 4101 MICR Printers, contact a representative via telephone at 304-232-0899, e-mail [email protected] or visit http://www.troygroup.com .

FDA Accepts Braeburn's New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder

Retrieved on: 
Thursday, December 8, 2022
Mitigation, Topical steroid withdrawal, SC, Urinary tract infection, Food, Opioid use disorder, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, OUD, Patient, Injection, Headache, Nausea, New Drug Application, Buprenorphine, FDA, Insomnia, Braeburn, CIII, Multimedia, Constipation, Safety, REMS, PDUFA, Pharmaceutical industry

PLYMOUTH MEETING, Pa., Dec. 8, 2022 /PRNewswire/ -- Braeburn announces that the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release weekly and monthly injections for subcutaneous (SC) use (CIII) for moderate to severe opioid use disorder was accepted by the U.S. Food and Drug Administration (FDA). The PDUFA action date is set for May 23, 2023. 

Key Points: 
  • PLYMOUTH MEETING, Pa., Dec. 8, 2022 /PRNewswire/ -- Braeburn announces that the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release weekly and monthly injections for subcutaneous (SC) use (CIII) for moderate to severe opioid use disorder was accepted by the U.S. Food and Drug Administration (FDA).
  • If approved, BRIXADI would be used as part of a complete treatment plan that includes counseling and psychosocial support.
  • BRIXADI will be available through a Risk Evaluation and Mitigation Strategy (REMS) program and administered only by healthcare providers in a healthcare setting.
  • Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder.

NLRB to Prosecute Braeburn Alloy Steel over Unfair Labor Practices

Retrieved on: 
Friday, October 14, 2022
Region 6, Metal, Collective bargaining, NLRB, United Steelworkers, National Labor Relations Board, USW, Public sector, Education, Paper, Multimedia, Glass, Braeburn, Lower Burrell, Pennsylvania, Hearing, Rubber industry in Malaysia, Mining

PITTSBURGH, Oct. 14, 2022 /PRNewswire/ -- The United Steelworkers (USW) today said that Region 6 of the National Labor Relations Board (NLRB) has issued a complaint against Braeburn Alloy Steel and its parent company, G.O.

Key Points: 
  • PITTSBURGH, Oct. 14, 2022 /PRNewswire/ -- The United Steelworkers (USW) today said that Region 6 of the National Labor Relations Board (NLRB) has issued a complaint against Braeburn Alloy Steel and its parent company, G.O.
  • USW Local 1324 represents about 30 workers at the Braeburn plant, which was acquired earlier this year by a subsidiary of G.O.
  • In its complaint released today, the NLRB set a hearing for Sept. 18, 2023, when an administrative law judge will hear the case against Braeburn Alloy Steel.
  • "All work has dignity, and the employees who made Braeburn Alloy Steel an attractive investment deserve a fair contract with union-negotiated pay and benefits as they remain loyal to their jobs," Hall said.

BLVD Communities Break Ground on Rehabilitation of 91-Unit Property in Providence, RI Preserving Much Needed Affordable Housing

Retrieved on: 
Monday, February 7, 2022
History of the National Register of Historic Places, BLVD, HAP, LIHTC, Braeburn, National Register of Historic Places, Income, Multimedia, Rehabilitation, Section 8 (housing), Community, BBQ, Housing, Lighting, Paint, National, LED, Acquisition, Property management

PROVIDENCE, R.I., Feb. 7, 2022 /PRNewswire/ --BLVD Communities announces the redevelopment of Braeburn and Chatham Apartments, a 91-unit affordable housing community located in Providence, Rhode Island.

Key Points: 
  • PROVIDENCE, R.I., Feb. 7, 2022 /PRNewswire/ --BLVD Communities announces the redevelopment of Braeburn and Chatham Apartments, a 91-unit affordable housing community located in Providence, Rhode Island.
  • "Preserving the existing housing stock of affordable rental homes is critically important for Rhode Island and its residents," said Carol Ventura, RIHousing's Executive Director.
  • BLVD Communities ("BLVD") is an owner, operator and developer of affordable housing nationwide.
  • BLVD's team has a proven record of successfully owning, developing and asset managing affordable housing with a current portfolio of 6,000 affordable units in 17 states.

Anthos Therapeutics Appoints David McIntyre as Chief Financial Officer

Retrieved on: 
Wednesday, January 5, 2022
Therapy, University, FXI, Federal Court of Australia, Thrombosis, Factor, Fuqua, Braeburn, Anthos, Partner, Bleeding, Master of Business Administration, Duke University, Lists of diseases, CEO, High Court, Accounting, Risk, Supreme court, AF, Bachelor of Laws, Business administration, Factor XI, Pharmaceutical industry, Economics

CAMBRIDGE, Mass., Jan. 5, 2022 /PRNewswire/ -- Anthos Therapeutics, a late-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the appointment of David McIntyre as Chief Financial Officer. Mr. McIntyre will assume responsibility for the company's finance and investor relation functions, and joins Anthos as its lead product candidate, abelacimab, expects to become the first 'hemostasis-sparring' Factor XI anticoagulant to enter Phase 3 clinical studies in the United States.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 5, 2022 /PRNewswire/ --Anthos Therapeutics, a late-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the appointment of David McIntyre as Chief Financial Officer.
  • "David brings a successful track record in both public and private healthcare companies and his financial, transactional, and legal experience adds significant value to our organization going forward."
  • Anthos Therapeutics is a late-stage biotechnology company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic diseases.
  • Anthos was launched by Blackstone Life Sciences in 2019.

FDA Accepts Braeburn's New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder

Retrieved on: 
Saturday, June 26, 2021
Opioids, Drugs, Psychoactive drugs, Food and Drug Administration, Morphinans, Drug rehabilitation, Ethers, Phenols, Buprenorphine, Prescription Drug User Fee Act, Opioid use disorder, Braeburn

PLYMOUTH MEETING, Pa., June26, 2021 /PRNewswire/ -- Braeburn announces that the New Drug Application (NDA)for BRIXADI (buprenorphine) extended-releaseweekly and monthlyinjection for subcutaneous (SC) use (CIII) for moderate to severe opioid use disorderwasaccepted bythe U.S. Food and Drug Administration (FDA).

Key Points: 
  • PLYMOUTH MEETING, Pa., June26, 2021 /PRNewswire/ -- Braeburn announces that the New Drug Application (NDA)for BRIXADI (buprenorphine) extended-releaseweekly and monthlyinjection for subcutaneous (SC) use (CIII) for moderate to severe opioid use disorderwasaccepted bythe U.S. Food and Drug Administration (FDA).
  • ThePrescription Drug User Fee Act (PDUFA) action date is set for December 15, 2021.
  • "We are pleased that the FDA has accepted our application for BRIXADI," said Mike Derkacz, President and CEO of Braeburn.
  • Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder.

Braeburn Announces Arbitration Determination that It Did Not Materially Breach Its License Agreement with Camurus AB

Retrieved on: 
Thursday, December 10, 2020
Camurus, Lund, Braeburn, Arbitration, Subcutaneous, Companies

PLYMOUTH MEETING, Pa., Dec. 10, 2020 /PRNewswire/ -- Braeburn announces that a tribunal appointed by the ICC International Court of Arbitration decided that Braeburn did not materially breach its license agreement with Camurus for the development and commercialization of an extended-release buprenorphine subcutaneous injection product.

Key Points: 
  • PLYMOUTH MEETING, Pa., Dec. 10, 2020 /PRNewswire/ -- Braeburn announces that a tribunal appointed by the ICC International Court of Arbitration decided that Braeburn did not materially breach its license agreement with Camurus for the development and commercialization of an extended-release buprenorphine subcutaneous injection product.
  • As a result of this decision, Braeburn retains all North American development and commercialization rights to the product as described in the license agreement, which remains in full effect.
  • This decision follows an arbitration hearing initiated by Braeburn in response to the issuance of a material breach notice from Camurus.
  • The decision, which is final as to all substantive bases alleged by Camurus, reserves a decision on the allocation of legal costs associated with the arbitration.